Boston, Mass-based Albireo Pharma said it has hit a phase 3 bull’s eye with Bylvay, an ileal bile acid transport inhibitor under investigation for the treatment of a rare pediatric liver disease called Alagille syndrome.
Source: Drug Industry Daily